Francois Meyer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12052124/publications.pdf

Version: 2024-02-01

41 papers

3,034 citations

172386 29 h-index 265120 42 g-index

42 all docs 42 docs citations

42 times ranked 3647 citing authors

#	Article	IF	CITATIONS
1	Insulin-like Growth Factors, Their Binding Proteins, and Prostate Cancer Risk: Analysis of Individual Patient Data from 12 Prospective Studies. Annals of Internal Medicine, 2008, 149, 461.	2.0	263
2	Randomized Trial of Antioxidant Vitamins to Prevent Acute Adverse Effects of Radiation Therapy in Head and Neck Cancer Patients. Journal of Clinical Oncology, 2005, 23, 5805-5813.	0.8	242
3	Antioxidant vitamin and mineral supplementation and prostate cancer prevention in the SU.VI.MAX trial. International Journal of Cancer, 2005, 116, 182-186.	2.3	212
4	A Randomized Trial of Antioxidant Vitamins to Prevent Second Primary Cancers in Head and Neck Cancer Patients. Journal of the National Cancer Institute, 2005, 97, 481-488.	3.0	209
5	High levels of PCBs in breast milk of inuit women from arctic quebec. Bulletin of Environmental Contamination and Toxicology, 1989, 43, 641-646.	1.3	187
6	Antioxidant vitamins supplementation and mortality: A randomized trial in head and neck cancer patients. International Journal of Cancer, 2006, 119, 2221-2224.	2.3	149
7	Antihypertensive Drug Use and The Risk of Prostate Cancer (Canada). Cancer Causes and Control, 2004, 15, 535-541.	0.8	140
8	Deletions of the INK4A Gene in Superficial Bladder Tumors. American Journal of Pathology, 1999, 155, 105-113.	1.9	121
9	Interaction between antioxidant vitamin supplementation and cigarette smoking during radiation therapy in relation to longâ€term effects on recurrence and mortality: A randomized trial among head and neck cancer patients. International Journal of Cancer, 2008, 122, 1679-1683.	2.3	106
10	Dietary fat and prostate cancer survival. Cancer Causes and Control, 1999, 10, 245-251.	0.8	93
11	Significance of MMP-2 expression in prostate cancer: an immunohistochemical study. Cancer Research, 2003, 63, 8511-5.	0.4	88
12	Health-Related Quality of Life As a Survival Predictor for Patients With Localized Head and Neck Cancer Treated With Radiation Therapy. Journal of Clinical Oncology, 2009, 27, 2970-2976.	0.8	83
13	Predictors of Severe Acute and Late Toxicities in Patients With Localized Head-and-Neck Cancer Treated With Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1454-1462.	0.4	81
14	DIETARY FAT AND ADVANCED PROSTATE CANCER. Journal of Urology, 1998, 159, 1271-1275.	0.2	75
15	Dosage, duration and timing of nonsteroidal antiinflammatory drug use and risk of prostate cancer. International Journal of Cancer, 2003, 106, 409-415.	2.3	69
16	Dietary energy and nutrients in relation to preclinical prostate cancer. Nutrition and Cancer, 1997, 29, 120-126.	0.9	67
17	Chromosome 9 deletions and recurrence of superficial bladder cancer: identification of four regions of prognostic interest. Oncogene, 2000, 19, 6317-6323.	2.6	62
18	Dietary Fat in Relation to Prognostic Indicators in Breast Cancer. Journal of the National Cancer Institute, 1988, 80, 819-825.	3.0	59

#	Article	IF	CITATIONS
19	NEOADJUVANT HORMONAL THERAPY BEFORE RADICAL PROSTATECTOMY AND RISK OF PROSTATE SPECIFIC ANTIGEN FAILURE. Journal of Urology, 1999, 162, 2024-2028.	0.2	58
20	Predictors of weight loss during radiotherapy in patients with stage I or II head and neck cancer. Cancer, 2010, 116, 2275-2283.	2.0	57
21	Genetic Polymorphisms and Head and Neck Cancer Outcomes: A Review. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 490-499.	1.1	55
22	DOWNWARD TREND IN PROSTATE CANCER MORTALITY IN QUEBEC AND CANADA. Journal of Urology, 1999, 161, 1189-1191.	0.2	50
23	Membrane-type-1 matrix metalloproteinase, matrix metalloproteinase 2, and tissue inhibitor of matrix proteinase 2 in prostate cancer: identification of patients with poor prognosis by immunohistochemistry. Human Pathology, 2008, 39, 731-739.	1.1	49
24	Lifetime occupational physical activity and incidental prostate cancer (Canada). Cancer Causes and Control, 2000, 11, 759-764.	0.8	41
25	Serum Prognostic Markers in Head and Neck Cancer. Clinical Cancer Research, 2010, 16, 1008-1015.	3.2	39
26	Validation of Genetic Sequence Variants as Prognostic Factors in Early-Stage Head and Neck Squamous Cell Cancer Survival. Clinical Cancer Research, 2012, 18, 196-206.	3.2	39
27	Factors associated with weight loss during radiotherapy in patients with stage I or II head and neck cancer. Supportive Care in Cancer, 2012, 20, 591-599.	1.0	39
28	Expression of p21 predicts PSA failure in locally advanced prostate cancer treated by prostatectomy. International Journal of Cancer, 2001, 95, 135-139.	2.3	33
29	Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes. International Journal of Cancer, 2000, 89, 100-104.	2.3	31
30	Dietary vitamin D intake and serum 25â€hydroxyvitamin D level in relation to disease outcomes in head and neck cancer patients. International Journal of Cancer, 2011, 128, 1741-1746.	2.3	28
31	Maternal and neonatal morbidity in instrumental deliveries with the kobayashi vacuum extractor and low forceps. Acta Obstetricia Et Gynecologica Scandinavica, 1987, 66, 643-647.	1.3	26
32	Insulin-Like Growth Factor Binding Protein 2: An Androgen-Dependent Predictor of Prostate Cancer Survival. European Urology, 2005, 47, 695-702.	0.9	26
33	Prognostic Significance of Cyclooxygenase-2 Overexpression in Glottic Cancer. Clinical Cancer Research, 2008, 14, 67-73.	3.2	25
34	Acute Adverse Effects of Radiation Therapy and Local Recurrence in Relation to Dietary and Plasma Beta Carotene and Alpha Tocopherol in Head and Neck Cancer Patients. Nutrition and Cancer, 2007, 59, 29-35.	0.9	24
35	A randomized controlled trial to test the efficacy of trans-tympanic injections of a sodium thiosulfate gel to prevent cisplatin-induced ototoxicity in patients with head and neck cancer. Journal of Otolaryngology - Head and Neck Surgery, 2019, 48, 4.	0.9	24
36	Matrix metalloproteinase 9 is associated with Gleason score in prostate cancer but not with prognosis. Human Pathology, 2010, 41, 1694-1701.	1.1	21

#	Article	IF	CITATIONS
37	A Prospective Study of the Insulin-Like Growth Factor Axis in Relation with Prostate Cancer in the SU.VI.MAX Trial. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 2269-2272.	1.1	18
38	Genetic sequence variants in vitamin D metabolism pathway genes, serum vitamin D level and outcome in head and neck cancer patients. International Journal of Cancer, 2013, 132, 2520-2527.	2.3	16
39	Genetic sequence variants and the development of secondary primary cancers in patients with head and neck cancers. Cancer, 2012, 118, 1554-1565.	2.0	15
40	Predictors of circulating INTERLEUKIN-6 levels in head and neck cancer patients. Cancers of the Head $\&$ Neck, 2018, 3, .	6.2	7
41	A genome-wide association study of non-HPV-related head and neck squamous cell carcinoma identifies prognostic genetic sequence variants in the MAP-kinase and hormone pathways. Cancer Epidemiology, 2016, 42, 173-180.	0.8	4